陆大雨
2021-03-17
不错
@美股研究社:
默沙东创新肾细胞癌疗法获FDA突破性疗法认定,并获优先评审资格
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP,发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":324982686,"tweetId":"324982686","gmtCreate":1615952491645,"gmtModify":1703495455538,"author":{"id":3577757168776840,"authorId":3577757168776840,"authorIdStr":"3577757168776840","name":"陆大雨","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>不错</p></body></html>","htmlText":"<html><head></head><body><p>不错</p></body></html>","text":"不错","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/324982686","repostId":324980923,"repostType":1,"repost":{"magic":2,"id":324980923,"tweetId":"324980923","gmtCreate":1615951734562,"gmtModify":1703495447619,"author":{"id":3503452965237041,"authorId":3503452965237041,"authorIdStr":"3503452965237041","name":"美股研究社","avatar":"https://static.tigerbbs.com/a239c7906133df1f3817d0746a8a0ba1","vip":6,"userType":6,"introduction":"玩赚美股最好的资讯平台,你想要的美股行情、热点都在这里!","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":59082,"starInvestorFlag":false},"themes":[],"images":[{"img":"https://static.tigerbbs.com/5e50b70bc8beac33e7680520ad5eacd5","width":"536","height":"300"}],"coverImages":[{"img":"https://static.tigerbbs.com/5e50b70bc8beac33e7680520ad5eacd5","width":"536","height":"300"}],"title":"默沙东创新肾细胞癌疗法获FDA突破性疗法认定,并获优先评审资格","extraTitle":"","html":"<html><head></head><body><p>美股研究社消息,智通财经APP获悉,<a target=\"_blank\" href=\"https://laohu8.com/S/MRK\">$默沙东(MRK)$</a> (MRK.US)宣布,美国FDA已经接受该公司为HIF-2α抑制剂belzutifan递交的新药申请(NDA),用于治疗Von Hippel-Lindau病(VHL)相关肾细胞癌(RCC)。此外,FDA授予了这一申请优先审评资格,预计在今年9月15日之前做出回复。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5e50b70bc8beac33e7680520ad5eacd5\" tg-width=\"536\" tg-height=\"300\"></p><p>这一申请是基于2期临床试验的结果,在VHL疾病相关RCC患者中,belzutifan达到36.1%(n=22/61)的确认总缓解率。默沙东目前还在晚期RCC和其它肿瘤类型中检验belzutifan的疗效。包括在3期临床试验中作为组合疗法的一部分,一线治疗晚期透明细胞RCC。</p><p>据悉,在2019年,默沙东通过收购Peloton公司获得belzutifan,该疗法目前已获得了FDA授予的突破性疗法认定。</p><p> 本文来源:美股研究社,转载请注明版权</p></body></html>","htmlText":"<html><head></head><body><p>美股研究社消息,智通财经APP获悉,<a target=\"_blank\" href=\"https://laohu8.com/S/MRK\">$默沙东(MRK)$</a> (MRK.US)宣布,美国FDA已经接受该公司为HIF-2α抑制剂belzutifan递交的新药申请(NDA),用于治疗Von Hippel-Lindau病(VHL)相关肾细胞癌(RCC)。此外,FDA授予了这一申请优先审评资格,预计在今年9月15日之前做出回复。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5e50b70bc8beac33e7680520ad5eacd5\" tg-width=\"536\" tg-height=\"300\"></p><p>这一申请是基于2期临床试验的结果,在VHL疾病相关RCC患者中,belzutifan达到36.1%(n=22/61)的确认总缓解率。默沙东目前还在晚期RCC和其它肿瘤类型中检验belzutifan的疗效。包括在3期临床试验中作为组合疗法的一部分,一线治疗晚期透明细胞RCC。</p><p>据悉,在2019年,默沙东通过收购Peloton公司获得belzutifan,该疗法目前已获得了FDA授予的突破性疗法认定。</p><p> 本文来源:美股研究社,转载请注明版权</p></body></html>","text":"美股研究社消息,智通财经APP获悉,$默沙东(MRK)$ (MRK.US)宣布,美国FDA已经接受该公司为HIF-2α抑制剂belzutifan递交的新药申请(NDA),用于治疗Von Hippel-Lindau病(VHL)相关肾细胞癌(RCC)。此外,FDA授予了这一申请优先审评资格,预计在今年9月15日之前做出回复。 这一申请是基于2期临床试验的结果,在VHL疾病相关RCC患者中,belzutifan达到36.1%(n=22/61)的确认总缓解率。默沙东目前还在晚期RCC和其它肿瘤类型中检验belzutifan的疗效。包括在3期临床试验中作为组合疗法的一部分,一线治疗晚期透明细胞RCC。 据悉,在2019年,默沙东通过收购Peloton公司获得belzutifan,该疗法目前已获得了FDA授予的突破性疗法认定。 本文来源:美股研究社,转载请注明版权","highlighted":1,"essential":1,"paper":2,"link":"https://laohu8.com/post/324980923","repostId":0,"isVote":1,"tweetType":1,"commentLimit":10,"symbols":["MRK"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":586,"xxTargetLangEnum":"ZH_CN"},"isVote":1,"tweetType":1,"viewCount":976,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/324982686"}
精彩评论